MyoKardia Announces Proposed Public Offering of Common Stock
March 25, 2019 16:01 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
MyoKardia to Present at Cowen & Co. 39th Annual Health Care Conference
March 06, 2019 08:00 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of serious...
MyoKardia Announces Positive Six-Month Safety and Efficacy Data from PIONEER-OLE Study of Mavacamten for the Treatment of Symptomatic, Obstructive HCM
March 04, 2019 08:02 ET
|
MyoKardia, Inc.
Mavacamten Well Tolerated; Results Show Statistically Significant Elimination of Obstruction and Durable NYHA Class Improvements Statistically Significant Improvement in Several Key Biomarkers...
MyoKardia Reports Fourth Quarter and Full Year 2018 Financial Results
February 28, 2019 08:30 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
MyoKardia Appoints William Fairey as Chief Commercial Officer
January 23, 2019 08:30 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
MyoKardia to Present at 37th Annual J.P. Morgan Healthcare Conference
January 03, 2019 08:00 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of...
MyoKardia Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi
January 02, 2019 08:00 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of...
MyoKardia Reports Positive Data from Phase 1b Single-Ascending Dose Clinical Trial of MYK-491 in Dilated Cardiomyopathy and Systolic Heart Failure Patients
December 11, 2018 08:30 ET
|
MyoKardia, Inc.
MYK-491 Demonstrated Increase in Contractility Consistent with Data from Preclinical and Healthy Volunteer Studies Multiple-Ascending Dose Phase 2a Clinical Trial in DCM and Systolic Heart Failure...
MyoKardia to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
December 05, 2018 16:01 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of...
MyoKardia Presents Preclinical Evidence of Mavacamten’s Novel Effect on Diastolic Compliance at the 2018 American Heart Association Scientific Sessions
November 12, 2018 07:30 ET
|
MyoKardia, Inc.
Improved Left Ventricular Compliance Demonstrated in Genetic Pig Model of Non-Obstructed Hypertrophic Cardiomyopathy Results Add to Growing Body of Evidence of Mavacamten’s Dual Activity in...